<DOC>
	<DOCNO>NCT01310894</DOCNO>
	<brief_summary>The aim study : - ass impact TOOKAD® Soluble-Vascular Targeted Photodynamic Therapy ( VTP ) rate absence definite cancer use patient active surveillance comparison ( co-primary objective A ) - determine difference rate treatment failure associate observed progression disease low risk prostate cancer moderate high risk prostate cancer men undergo TOOKAD® Soluble-VTP compare men active surveillance ( co-primary objective B ) .</brief_summary>
	<brief_title>Efficacy Safety Study TOOKAD® Soluble Localised Prostate Cancer Compared Active Surveillance .</brief_title>
	<detailed_description>This Phase 3 , multicentre , open label , randomise control study subject diagnose low risk prostate cancer TransRectal Ultrasound ( TRUS ) guide biopsy . Subjects randomise either Active Surveillance TOOKAD® Soluble VTP . Subjects remain study approximately 24 month follow randomisation . A total 400 subject enter study ; 200 receive Active Surveillance 200 receive TOOKAD® Soluble-VTP .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Subjects eligible inclusion study follow criterion meet : 1 . Low risk prostate cancer diagnose use one transrectal ultrasound guide biopsy ( TRUS ) use 10 24 core perform less 12 month prior enrolment , show follow : Gleason 3 + 3 prostate adenocarcinoma maximum , Two ( 2 ) three ( 3 ) core positive cancer A maximum cancer core length 5 mm core . 2 . Cancer clinical stage T2a ( pathological radiological T2c disease permit ) 3 . Serum prostate specific antigen ( PSA ) 10 ng/mL less 4 . Prostate volume equal great 25 cc less 70 cc . 5 . Male subject age 18 year old . Subjects eligible study meeting follow criterion : 1 . Unwillingness accept randomisation either two arm study 2 . Any prior current treatment prostate cancer , include surgery , radiation therapy ( external brachytherapy ) chemotherapy . 3 . Any surgical intervention benign prostatic hypertrophy 4 . Life expectancy le 10 year . 5 . Any condition history illness surgery may pose additional risk men undergo VTP procedure . 6 . Participation another clinical study recipient investigational product within 1 month study entry . 7 . Subject unable understand patient 's information document , give consent complete study task . 8 . Subject custody residence nursing home rehabilitation facility 9 . Contraindication Magnetic resonance Imaging ( MRI ) ( e.g. , pacemaker , history allergic reaction gadolinium ) , factor exclude accurate reading pelvic MRI ( e.g. , hip prosthesis ) 10 . Any condition history illness surgery may pose additional risk men undergo TOOKAD® Soluble VTP procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostatic Disease</keyword>
	<keyword>Genital Neoplasm , male</keyword>
	<keyword>Urogenital neoplasm</keyword>
	<keyword>Genital disease , male</keyword>
	<keyword>Male urogenital disease</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasms site</keyword>
	<keyword>Prostatic neoplasm</keyword>
	<keyword>Carcinoma</keyword>
</DOC>